Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 1,783	$ 7,947,460	$ (9,018,306)	$ (1,069,063)
Balance, shares at Dec. 31, 2022	17,272,116
Stock-based compensation		78,509		78,509
Net loss			(510,643)	(510,643)
Balance at Mar. 31, 2023	$ 1,783	8,025,969	(9,528,949)	(1,501,197)
Balance, shares at Mar. 31, 2023	17,272,116
Balance at Dec. 31, 2022	$ 1,783	7,947,460	(9,018,306)	(1,069,063)
Balance, shares at Dec. 31, 2022	17,272,116
Net loss				(1,549,253)
Balance at Sep. 30, 2023	$ 1,814	9,483,216	(10,567,559)	(1,082,529)
Balance, shares at Sep. 30, 2023	17,588,811
Balance at Dec. 31, 2022	$ 1,783	7,947,460	(9,018,306)	$ (1,069,063)
Balance, shares at Dec. 31, 2022	17,272,116
Exercise of stock options, shares
Balance at Dec. 31, 2023	$ 1,764	9,701,774	(11,109,195)	$ (1,405,657)
Balance, shares at Dec. 31, 2023	17,635,478
Balance at Mar. 31, 2023	$ 1,783	8,025,969	(9,528,949)	(1,501,197)
Balance, shares at Mar. 31, 2023	17,272,116
Stock-based compensation		78,509		78,509
Net loss			(352,143)	(352,143)
Balance at Jun. 30, 2023	$ 1,783	8,104,478	(9,881,092)	(1,774,831)
Balance, shares at Jun. 30, 2023	17,272,116
Stock-based compensation		428,683		428,683
Net loss			(686,467)	(686,467)
Retirement of due to Sanovas through The issuance of shares of common stock To Sanovas Opthalmology LLC	$ 31	950,055		950,086
Retirement of due to Sanovas through The issuance of shares of common stock To Sanovas Opthalmology LLC, shares	316,695
Balance at Sep. 30, 2023	$ 1,814	9,483,216	(10,567,559)	(1,082,529)
Balance, shares at Sep. 30, 2023	17,588,811
Balance at Dec. 31, 2023	$ 1,764	9,701,774	(11,109,195)	(1,405,657)
Balance, shares at Dec. 31, 2023	17,635,478
Settlement of accounts payable through issuance of shares	$ 7	149,993		150,000
Settlement of accounts payable through issuance of shares, shares	75,000
Stock-based compensation		1,732,834		1,732,834
Exercise of stock options	$ 15	149,985		150,000
Exercise of stock options, shares	150,000
Net loss			(2,145,876)	(2,145,876)
Balance at Mar. 31, 2024	$ 1,786	11,734,586	(13,255,071)	(1,518,699)
Balance, shares at Mar. 31, 2024	17,860,478
Balance at Dec. 31, 2023	$ 1,764	9,701,774	(11,109,195)	$ (1,405,657)
Balance, shares at Dec. 31, 2023	17,635,478
Exercise of stock options, shares				170,000
Net loss				$ (3,453,800)
Balance at Sep. 30, 2024	$ 1,806	12,706,875	(14,562,995)	(1,854,314)
Balance, shares at Sep. 30, 2024	18,060,517
Balance at Mar. 31, 2024	$ 1,786	11,734,586	(13,255,071)	(1,518,699)
Balance, shares at Mar. 31, 2024	17,860,478
Stock-based compensation		211,009		211,009
Exercise of stock options	$ 2	59,998		60,000
Exercise of stock options, shares	20,000
Net loss			(663,633)	(663,633)
Shares sold to investors	$ 4	99,996		100,000
Shares sold to investors, shares	44,444
Balance at Jun. 30, 2024	$ 1,792	12,105,589	(13,918,704)	(1,811,323)
Balance, shares at Jun. 30, 2024	17,924,922
Stock-based compensation		296,256		296,256
Net loss			(644,291)	(644,291)
Shares sold to investors	$ 14	305,030		305,044
Shares sold to investors, shares	135,595
Balance at Sep. 30, 2024	$ 1,806	$ 12,706,875	$ (14,562,995)	$ (1,854,314)
Balance, shares at Sep. 30, 2024	18,060,517

RetinalGenix Technologies Inc. 10-Q